| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenues | — | — | — | $0 | $0 |
| Research and development | $446K-96.2% | $11.8M-66.8% | $35.6M+7.1% | $33.3M+63.1% | $20.4M |
| General and administrative | $3.3M-55.8% | $7.5M-22.0% | $9.6M-7.1% | $10.3M+3.4% | $10.0M |
| Asset impairment loss | $403K | — | — | $1.9M | — |
| Total operating expenses | $4.2M-78.5% | $19.3M-60.1% | $48.4M+6.5% | $45.5M+49.6% | $30.4M |
| Loss from operations | -$4.2M+78.5% | -$19.3M+60.1% | -$48.4M-6.5% | -$45.5M-49.6% | -$30.4M |
| Interest expense, net | -$24K+98.0% | -$1.2M-13078.2% | -$9K | — | — |
| Write-off related party note receivable | -$600K | — | — | — | — |
| Change in fair value of contingent consideration and derivative financial instruments | -$4.1M-153.8% | $7.6M+965.9% | -$878K-311.5% | $415K | — |
| Inducement expense | -$2.6M | — | — | — | — |
| Loss before income taxes | -$8.3M+48.8% | -$16.2M+67.2% | -$49.3M-9.4% | -$45.1M-37.8% | -$32.7M |
| Income tax benefit (expense) | $3.0M | — | $409K-85.8% | $2.9M | $0 |
| Net loss | -$8.3M+37.3% | -$13.2M+73.0% | -$48.9M-15.9% | -$42.2M-29.0% | -$32.7M |
| Weighted-average common shares outstanding basic | 9.4M+7556.5% | 123K+54.7% | 79K-97.9% | 3.8M-94.6% | 70.3M |
| Weighted-average common shares outstanding diluted | 9.4M+7556.5% | 123K+54.7% | 79K-97.9% | 3.8M-94.6% | 70.3M |
| Net loss per common share basic | -$0.88+99.2% | -$107.35+82.6% | -$616.07-5077.1% | -$11.90-2431.9% | -$0.47 |
| Net loss per common share diluted | -$0.88+99.2% | -$107.35+82.6% | -$616.07-5077.1% | -$11.90-2431.9% | -$0.47 |
Source: SEC EDGAR XBRL. % change vs prior period shown where available.
Source: SEC EDGAR 10-K and 10-Q filings. Up to 10 years annual / 16 quarters shown.